Literature DB >> 31468273

Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis.

Eleanor M Eckert1, Kelli C Dominick2,3, Ernest V Pedapati2,3, Logan K Wink2,3, Rebecca C Shaffer4,5, Howard Andrews6, Tse-Hwei Choo7, Chen Chen7, Walter E Kaufmann8,9, Nicole Tartaglia10, Elizabeth M Berry-Kravis11, Craig A Erickson12,13,14.   

Abstract

Using a dataset involving 415 individuals with irritability, aggression, agitation and self-injury (IAAS) behaviors from the fragile X syndrome (FXS) FORWARD database, we describe the psychopharmacologic management of IAAS and features of the population of persons with FXS treated with drug therapy for IAAS. Among those with FXS exhibiting IAAS, individuals with FXS receiving drug treatment of IAAS were older, more predominantly male, have more significant intellectual disability, more like to have comorbid autism, hyperarousal, and social impairments. The most commonly utilized medications for IAAS in FXS are antipsychotic medications, specifically aripiprazole and risperidone (37% and 27%, respectively). The majority of subjects (63%) experienced no side effects noted from the use of their psychopharmacologic medications.

Entities:  

Keywords:  Fragile X syndrome; Irritability; Pharmacotherapy

Mesh:

Substances:

Year:  2019        PMID: 31468273      PMCID: PMC8211361          DOI: 10.1007/s10803-019-04173-z

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  38 in total

1.  Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome.

Authors:  W E Kaufmann; M T Abrams; W Chen; A L Reiss
Journal:  Am J Med Genet       Date:  1999-04-02

2.  Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.

Authors:  Walter E Kaufmann; Sharon A Kidd; Howard F Andrews; Dejan B Budimirovic; Amy Esler; Barbara Haas-Givler; Tracy Stackhouse; Catharine Riley; Georgina Peacock; Stephanie L Sherman; W Ted Brown; Elizabeth Berry-Kravis
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

3.  FORWARD: A Registry and Longitudinal Clinical Database to Study Fragile X Syndrome.

Authors:  Stephanie L Sherman; Sharon A Kidd; Catharine Riley; Elizabeth Berry-Kravis; Howard F Andrews; Robert M Miller; Sharyn Lincoln; Mark Swanson; Walter E Kaufmann; W Ted Brown
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

Review 4.  Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).

Authors:  Katrina Williams; Amanda Brignell; Melinda Randall; Natalie Silove; Philip Hazell
Journal:  Cochrane Database Syst Rev       Date:  2013-08-20

5.  Aggression in fragile X syndrome.

Authors:  A C Wheeler; M Raspa; E Bishop; D B Bailey
Journal:  J Intellect Disabil Res       Date:  2015-12-02

6.  Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey.

Authors:  Donald B Bailey; Melissa Raspa; Murrey Olmsted; David B Holiday
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

Review 7.  Antipsychotics in the treatment of autism.

Authors:  David J Posey; Kimberly A Stigler; Craig A Erickson; Christopher J McDougle
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 8.  Psychopharmacology in fragile X syndrome--present and future.

Authors:  Elizabeth Berry-Kravis; Kristina Potanos
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004

9.  The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

Authors:  M G Aman; N N Singh; A W Stewart; C J Field
Journal:  Am J Ment Defic       Date:  1985-03

Review 10.  Fragile X targeted pharmacotherapy: lessons learned and future directions.

Authors:  Craig A Erickson; Matthew H Davenport; Tori L Schaefer; Logan K Wink; Ernest V Pedapati; John A Sweeney; Sarah E Fitzpatrick; W Ted Brown; Dejan Budimirovic; Randi J Hagerman; David Hessl; Walter E Kaufmann; Elizabeth Berry-Kravis
Journal:  J Neurodev Disord       Date:  2017-06-12       Impact factor: 4.025

View more
  4 in total

1.  Effects of clonidine on progressive ratio schedule performance in Fmr1 knockout mice.

Authors:  Craige C Wrenn; Eric French; Dustin Baker; Randall McCallian; Ryan Kirk; Mark P Reilly; Maria G Valdovinos
Journal:  Psychopharmacology (Berl)       Date:  2021-01-15       Impact factor: 4.530

Review 2.  Toward Actionable Practice Parameters for "Dual Diagnosis": Principles of Assessment and Management for Co-Occurring Psychiatric and Intellectual/Developmental Disability.

Authors:  John N Constantino; Shae Strom; Michael Bunis; Cy Nadler; Teresa Rodgers; Julia LePage; Connie Cahalan; Amber Stockreef; Lucas Evans; Rachel Jones; Alyssa Wilson
Journal:  Curr Psychiatry Rep       Date:  2020-02-01       Impact factor: 5.285

3.  Effects of Irritability of the Youth on Subjective Well-Being: Mediating Effect of Coping Styles.

Authors:  Ling Zhang; Benxian Yao; Xiaodan Zhang; Hao Xu
Journal:  Iran J Public Health       Date:  2020-10       Impact factor: 1.429

4.  Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study.

Authors:  Dejan B Budimirovic; Kelli C Dominick; Lidia V Gabis; Maxwell Adams; Mathews Adera; Linda Huang; Pamela Ventola; Nicole R Tartaglia; Elizabeth Berry-Kravis
Journal:  Front Pharmacol       Date:  2021-10-08       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.